Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470

Press ReleaseNicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated robust efficacy and safety in topline results from first Phase 3 trial, Mont BlancJuly 25, 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced the recruitment and...

Biot, 25/07/2024 (informazione.news - comunicati stampa - salute e benessere)

Attachment